Lydie Trautmann, Ph.D.
Principal Investigator
Viral Pathogenesis & Therapeutics


Lydie Trautmann, Ph.D., is a principal investigator at the Vaccine & Gene Therapy Institute of Florida (VGTI Florida®). She is an expert in the role of immune cells that kill infected cells thereby controlling virus infections. She is also actively involved in defining how chronic viral infections result in immune dysfunction. Her work has been published in 26 articles in scientific journals.

Dr. Trautmann has extensively studied disease development following infection with the HIV virus. She has contributed to identifying a molecule called PD-1 that suppresses the body’s immune response to HIV infection, which has led to clinical trials targeting this molecule to help improve the immune system’s capacity to fight HIV infection. Her recent research has focused on understanding the early immunological events occurring after infection or vaccination to identify key factors and mechanisms determining the efficiency of the immune response on a molecular level.

Dr. Trautmann has earned a number of prestigious honors for her work, including fellowships from the Cancer Research Association of France, the Foundation for Medical Research in France, the French National League Against Cancer, and the Canadian Institutes of Health Research.

She earned her bachelor’s degree in biological sciences and master’s degree in biotechnology from Louis Pasteur University in Strasbourg, France. She also holds a biotechnology engineering degree from the Strasbourg Graduate School of Biotechnology, and a doctorate in immunology from the University of Paris Rene Descartes. She conducted her post-doctoral training at the University of Montreal.
Laboratory of Dr. Trautmann 
Dr. Lydie Trautmann’s laboratory is focused on understanding the early immunological events occurring after infection and vaccination. Two different areas of research focused on CD8 T cells are currently being pursued: 
  1. Defining the mechanisms of CD8 T cell immune dysfunction in acute HIV infection, 
  2. Defining the factors affecting the CD8 T cell immune response in successful vaccines 

The identification of mechanisms that allow for an efficient  vs. a dysfunctional CD8 T cell immune response will provide clues for therapeutic strategies to control viral replication and dissemination of HIV and would be critical for the development of new therapeutic strategies and vaccines for HIV and other infectious agents.

Research Projects
Analyzing early immunological events in HIV infection to define how HIV infection leads to CD8 T cell dysfunction and lack of T cell memory. 
The first immunological events that occur after HIV exposure might play a crucial role in the viral control and determine the disease outcome. Our studies highlighted the role of PD-1 in T-cell dysfunction in the chronic phase of infection and also showed a pronounced T-cell dysfunction in the early phase of HIV infection. Using a multi-pronged approach, we are dissecting the mechanisms and the TCR repertoire of the early CD8 T cell immune response to the virus in individuals during acute infection and under antiretroviral treatment to define how HIV infection leads to CD8 T cell dysfunction. The identification of mechanisms leading to immune dysfunction and protection should provide clues for strategies to control viral replication and dissemination of HIV. 
Characterizing the effector and memory immune responses to efficient vaccines. 
Successful vaccines induce the generation of specific immune memory that can provide lifelong protection. Developed empirically in the 1930's, the yellow fever vaccine represents one of the most successful vaccines ever made. We are using highly sensitive techniques to define mechanisms and key factors that would be predictive of protective immunity in response to the yellow fever vaccine. We are analyzing the effector and memory immune responses as well as their TCR repertoire in individuals receiving immunization of different vaccines. Understanding the determinants of an efficient immune response upon vaccination will be crucial to design new T-cell based vaccine strategies.

Contact Information

Lydie Trautmann, Ph.D.
Principal Investigator
Vaccine & Gene Therapy Institute of Florida
9801 SW Discovery Way
Port St. Lucie, FL 34987
Tel: (772) 345-5671
Fax: (772) 345-0625
Lab Members
Tel: (772) 345-5683
Fax: (772) 345-0625
Pearline Ngauv, M.Sc. - 
Divya Srinivasan, M.Sc. - 



  1. Trautmann L, Mbitikon-Kobo FM, Goulet JP, Peretz Y, Shi Y, Van Grevenynghe J, Procopio F, Boulassel MR, Routy JP, Chomont N, Haddad EK and Sekaly RP. Profound Metabolic, Functional and Cytolytic Differences Characterize HIV-Specific CD8 T Cells in Primary and Chronic HIV Infection. Blood 2012 120(17):3466-77
  2. Janbazian L, Price DA, Canderan G, Filali-Mouhim A, Asher TE, Ambrozak DR, Scheinberg P, Boulassel MR, Routy JP, Koup RA, Douek DC, Sekaly RP, Trautmann L. Clonotype and Repertoire Changes Drive the Functional Improvement of HIV-Specific CD8 T Cell Populations under Conditions of Limited Antigenic Stimulation. J Immunol. 2012 Feb 1;188(3):1156-67. Epub 2011 Dec 30.
  3. Mbitikon-Kobo FM, Bonneville M, Sekaly RP, Trautmann L. Ex vivo measurement of the cytotoxic capacity of human primary antigen-specific CD8 T cells. J Immunol Methods. 2012 Jan 31;375(1-2):252-7. Epub 2011 Oct 5.
  4. H. Perrin, G. Canderan, R.P. Sekaly, L. Trautmann. New approaches to design HIV-1 T cell vaccines. 2010. Current Opinion in HIV & AIDS.5:368-376.
  5. E.A. Said, F.P. Dupuy, L. Trautmann, Y. Zhang, Y. Shi, M. El-Far, B.J. Hill, A. Noto, P. Ancuta, Y. Peretz, S.G. Fonseca, J. Van Grevenynghe, M.R. Boulassel, J. Bruneau, N.H. Shoukry, J.P. Routy, D.C. Douek, E.K. Haddad, R.P. Sekaly. PD-1 Induced IL-10 Production by Monocytes Impairs CD4 T-Cell Activation during HIV Infection. Nat Med 2010 Apr;16(4):452-9
  6. N. Chomont, M. El-Far, P. Ancuta, L. Trautmann, F.A. Procopio, B. Yassine-Diab, G. Boucher, M.R. Boulassel, G. Ghattas, J. M Brenchley, T. W Schacker, B. J Hill, D. C Douek, J.P. Routy, E.K. Haddad, R.P. Sekaly. 2009. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009 Aug;15(8):893-900
  7. Trautmann L. , L. Janbazian, N. Chomont, E.A. Said, S. Gimmig, B. Bessette, M.R. Boulassel, E. Delwart, H. Sepulveda, R. S Balderas, J.P. Routy, E.K. Haddad and R.P. Sekaly. 2006. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med. Oct;12(10):1198-202
  8. Trautmann L., M. Rimbert, K. Echasserieau, X. Saulquin, B. Neveu, J. Dechanet, V. Cerundolo, M. Bonneville. 2005. Selection of T cell clones expressing high-affinity public TCRs within Human cytomegalovirus-specific CD8 T cell responses. J Immunol. 175(9):6123-32
  9. Trautmann L., N. Labarrière, F. Jotereau, V. Karanikas, N.Gervois, T. Connerotte, P. Coulie and M. Bonneville. 2002. Dominant TCR Va usage by virus and tumor reactive T cells with wide affinity ranges for their specific antigens.  Eur J Immunol 32(11) : 3181-3190

Read More